

46. Skysta embolizacinė medžiaga su skysta kontrastine medžiaga



May be used with



PHIL™ The Difference

Free From Preparation and Tantalum Constraints

46. Skysta embolizacinė medžiaga su skysta kontrastine medžiaga



Key Clinical Benefits:

What is PHIL™?

The PHIL™ System is a non-adhesive liquid embolic agent comprised of a biocompatible polymer dissolved in dimethyl sulfoxide (DMSO) solvent. An Iodine component is covalently bonded to the polymer to provide homogeneous fluoroscopic visualization.

Polimeras su jodo junginiu
homogeniškam rentgenokontrastiškumui

The PHIL™ Liquid Embolic is intended for use in the embolization of lesions in the peripheral and neurovasculature, including arteriovenous malformations and hypervascular tumors.

Skirtas arterioveninėms
malformacijoms,
hipervaskuliariems navikams,
kraujagyslių pažeidimams
embolizuoti

Skysto kopolimero ir
dimetilsulfoksido
(DMSO) tirpalas

1 READY TO USE DEVICE

Pre-filled sterile syringes

- No preparation required
- No risk of contamination and needle stick injury
- High embolic capacity loaded in a 1mL syringe
(See *Embolic Capacity Chart* on flap)

Scepter balloon catheter
inflation in the Middle
Meningeal Artery




Figure 1

Tentorial AVF treated with PHIL™ and Competitor A Liquid Embolic injection through Scepter balloon catheter.




Figure 2

Coronal CT Reconstruction of Posterior Fossa AVM.

2 OPTIMIZED VISIBILITY

Iodine component is covalently bonded to the co-polymer

- No shaking needed
- Perfect homogeneity of PHIL™ radiopacity (Figure 1)
- Same visibility regardless the procedure length

Lower density of radiopacity

- Perfect balance between visibility and cast masking effect
- Visibility of microcatheter tip during treatment (Figure 1)

Jodo komponentas yra kovalentiškai sujungtas su kopolimeru

- Nereikia kratyti
- Puikus PHIL radiopralaidumo homogeniškumas (1 pav.)
- Toks pat matomumas, nepaisant procedūros trukmės

Mažesnis radiopralaidumo tankis

- Puiki matomumo ir liejinio maskavimo efekto pusiausvyra – Mikrokateterio antgalio matomumas gydymo metu



3 NO METALLIC COMPONENTS

No risk of microcatheter blockage due to Tantalum aggregation

Minimize (streak) artifact during control imaging (Figure 2)

- Facilitate staged procedures or combined treatments

Compatible with surgical resection

- No hazard related to sparking/combustion

No tattoo effect seen in superficial malformation treatment

Nėra mikrokateterio užsikimšimo rizikos dėl Tantalo agregacija

Sumažinkite artefaktą (juosteles) kontrolinio vaizdavimo metu (2 pav.)

- Palengvinti etapines procedūras arba kombinuotą gydymą

Suderinamas su chirurgine rezekcija


- Nėra pavojaus, susijusio su kibirkščiavimu/degimu

Tatuiruotės efekto nepastebėta gydant paviršinius apsigimimus

46. Skysta embolizacinė medžiaga su skysta kontrastine medžiaga

EMBOLIC CAPACITY

mL's of Precipitate Volume per mL of Liquid Embolic



PHIL™ vs. Competitor A

(similar viscosity to PHIL™ 25%)

Embolic Capacity Comparison

Product Precipitate Volume in
1 mL of Liquid Embolic

Competitor A • 0.67 mL

PHIL™ 25% • 0.85 mL

1 mL of PHIL™ 25% = 1.26 mL of Competitor A

PHIL™ 30% • 0.87 mL

1 mL of PHIL™ 30% = 1.3 mL of Competitor A

PHIL™ 35% • 0.90 mL

1 mL of PHIL™ 35% = 1.4 mL of Competitor A



Organizme kietėja
nekaisdamas,
precipituoja prie
sienelių

Cross section at
30 seconds

Precipitate dissected after soaking
in 37°C Phosphate Buffered Saline (PBS)




Cross section at
2 minutes


46. Skysta embolizacinė medžiaga su skysta kontrastine medžiaga

CASE STUDY


Transosseous Arteriovenous Malformation/Fistula




Arteriovenous shunt fed via ophthalmic artery



After complete occlusion of the vascular lesion
with PHIL™ 25% via transvenous access



No remaining vascular pathology after
PHIL™ injection



Distribution of PHIL™ after end of procedure

*Images courtesy of Dr. Markus Holtmannspötter
University of Copenhagen
Rigshospitalet, Denmark*

Skirtingų koncentracijų / klampumų:

25% (žemas klampumas),

30% (vidutinis klampumas),

35% (aukštas klampumas)

PHIL™ FORMULATIONS

Product Code Concentration Viscosity Volume of LE When to Use

LEN10250

PHIL™ 25%

16cSt

1mL

- Low flow scenarios
- Distal access

LEN10300

PHIL™ 30%

36cSt

1mL

- Moderate flow scenarios
- When feeding pedicle injections are conducted close to the nidus

LEN10350

PHIL™ 35%

72cSt

1mL

- Higher flow scenarios
- Large fistulous components embolization

MICROCATHETER COMPATIBILITY

PHIL™ must be used with DMSO compatible catheters such as:

Product Name	Description	Dead Space (mL)	Dead Space with PHIL™ Adaptor (mL)
Scepter C*	Compliant Occlusion Balloon	0.44	0.23
Scepter XC*	X-tra Compliant Occlusion Balloon	0.44	0.23
Headway® 17	Headway® 17 Microcatheter	0.41	0.26
Headway® Duo 156cm	Headway® Duo Microcatheter	0.34	0.24
Headway® Duo 167cm	Headway® Duo Microcatheter	0.35	0.25

Concentration:

Percentage of embolic material in DMSO in weight

Viscosity:

Measure in centistokes (ex: water = 1cSt, Blood = 5cSt)

Volume of Liquid Embolic:

DMSO + Copolymer bounded with iodine



PHIL™ SYSTEM COMPONENTS

1mL of PHIL™ system in pre-filled sterile syringe

1mL of DMSO in pre-filled sterile syringe

Catheter specific adaptors

Instructions for Use

MicroVention®
TERUMO
microvention.com

MicroVention, Inc.
Worldwide Headquarters
1311 Valencia Avenue
Tustin, CA 92780 USA
PH +1.714.247.8000
PH 1.800.990.8368

MicroVention UK Limited
Suite 3, The Barracks Building
10 Cliffords Fort, North Shields
Tyne and Wear, NE30 1JE
United Kingdom
PH +44 (0) 191 258 6777
F +44 (0) 191 258 5999

MicroVention Europe, S.A.R.L.
30 bis, rue du Vieil Abreuvoir
78100 Saint-Germain-en-Laye
France
PH +33 (1) 39 21 77 46
F +33 (1) 39 21 16 01

MicroVention Deutschland GmbH
Hildebrandtstr. 4 F
D-40215 Düsseldorf
Germany
PH +49 211 210 798-0
F +49 211 210 798-29

MICROVENTION, Headway, Scepter C and Scepter XC are a registered trademarks of MicroVention, Inc. PHIL is a trademark of MicroVention.
• Scientific and clinical data related to this document are on file at MicroVention, Inc. Refer to Instructions for Use, contraindications and warnings for additional information. ©2015 MicroVention, Inc. MM412(i) 6/15

